Montano C Brendan, Jackson W Clay, Vanacore Denise, Weisler Richard H
Montano Wellness LLC, Cromwell, CT, USA.
Department of Family Medicine, University of Connecticut Medical School, Farmington, CT, USA.
Neuropsychiatr Dis Treat. 2022 Apr 12;18:867-879. doi: 10.2147/NDT.S337703. eCollection 2022.
Primary care clinicians have a vital role to play in the diagnosis and management of patients with major depressive disorder (MDD). This includes screening for MDD as well as identifying other possible psychiatric disorders including bipolar disorder and/or other comorbidities. Once MDD is confirmed, partnering with patients in the shared decision-making process while considering different treatment options and best management of MDD over the course of their illness is recommended. Vortioxetine has been approved for the treatment of adults with MDD since 2013, and subsequent US label updates indicate that vortioxetine may be particularly beneficial for specific populations of patients with MDD, including those with treatment-emergent sexual dysfunction and patients experiencing certain cognitive symptoms. Given these recent label updates, this prescribing guide for vortioxetine aims to provide clear and practical guidance for primary care clinicians on the safe and effective use of vortioxetine for the treatment of MDD, including how to identify appropriate patients for treatment.
基层医疗临床医生在重度抑郁症（MDD）患者的诊断和管理中发挥着至关重要的作用。这包括对MDD进行筛查，以及识别其他可能的精神疾病，包括双相情感障碍和/或其他合并症。一旦确诊为MDD，建议在共同决策过程中与患者合作，同时考虑不同的治疗方案以及在患者病程中对MDD的最佳管理。自2013年以来，伏硫西汀已被批准用于治疗成人MDD，随后美国药品标签更新表明，伏硫西汀可能对特定的MDD患者群体特别有益，包括那些出现治疗引起的性功能障碍的患者以及经历某些认知症状的患者。鉴于这些最近的标签更新，本伏硫西汀处方指南旨在为基层医疗临床医生提供关于安全有效使用伏硫西汀治疗MDD的清晰实用指导，包括如何识别适合治疗的患者。
